The Biotech VoyagerBiotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.enTue, 16 Jun 2026 03:41:12 -0000Wed, 10 Jun 2026 05:24:19 -0000https://rss2.flightcast.com/mqgdnt7xpwdr8a9wwi6vadfl.xmlFlightcast RSS Feed GeneratorThe Biotech Voyagerhttps://files.flightcast.com/workspaces/bgjz0vjq242xtrgeo150iwjx/01KS131W696HVS5JX79QREQ3ZB/socials_profile_white.jpghttps://rss2.flightcast.com/mqgdnt7xpwdr8a9wwi6vadfl.xmlepisodicJeff MartinBen Mcleod and Jeff Martinsocials@flyte.bioBiotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.falseno3D Tissue Printing in SPACE & The Rise of Protein DegradersWelcome to The Biotech Voyager. It's the live show that covers where the puck is going in biotech.flightcast:ehoncdu03faniaofdry8xcxaWed, 10 Jun 2026 05:24:19 -0000Welcome to The Biotech Voyager. It's the live show that covers where the puck is going in biotech.

]]>3D Tissue Printing in SPACE & The Rise of Protein Degradersfull5891falseWelcome to The Biotech Voyager. It's the live show that covers where the puck is going in biotech.Cancer Therapeutics Roar, and the Founders of Tolemy Bio (and VelociTx) Join the ShowWelcome to The Biotech Voyager. It's the show that covers what's next in biotech.flightcast:j30o5j3ahqj2pnxqv5lbitz1Fri, 05 Jun 2026 04:55:44 -0000Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

]]>Cancer Therapeutics Roar, and the Founders of Tolemy Bio (and VelociTx) Join the Showfull5537falseWelcome to The Biotech Voyager. It's the show that covers what's next in biotech.OSCO Highlights, GLP1 Gene Therapy, and NK Cell Therapy for Lung RepairWelcome to The Biotech Voyager - it's the show that covers what's next in biotech.flightcast:dkreu4fuam25r7knp2zfze3oWed, 03 Jun 2026 04:53:58 -0000Welcome to The Biotech Voyager - it's the show that covers what's next in biotech.

]]>OSCO Highlights, GLP1 Gene Therapy, and NK Cell Therapy for Lung Repairfull5866falseWelcome to The Biotech Voyager - it's the show that covers what's next in biotech.Bacterial Tx go Viral, mRNA degraders, & Doudna's CRISPR company puts its first drug into a humanThe Biotech Voyager is the show that covers what's next in biotech.flightcast:txal3tglmh3owa7x0xpdmgddFri, 29 May 2026 04:56:15 -0000The Biotech Voyager is the show that covers what's next in biotech.

]]>Bacterial Tx go Viral, mRNA degraders, & Doudna's CRISPR company puts its first drug into a humanfull6110falseThe Biotech Voyager is the show that covers what's next in biotech.tRNA Therapies Make a Statement, In vivo CAR-T Rises, and Much MoreThe live show that covers what's next in biotech. Join us live!flightcast:ew2e0ql068ot3i6b4kge9sr3Fri, 22 May 2026 05:20:07 -0000The live show that covers what's next in biotech.

Join us live!

]]>tRNA Therapies Make a Statement, In vivo CAR-T Rises, and Much Morefull6157falseThe live show that covers what's next in biotech. Join us live!Molecular Glues Roar, Plus Gene Therapy and Cell Therapy NewsWelcome to The Biotech Voyager. It's the show that covers what's next in biotech.flightcast:wr5a8nb4gz1p3uxzqwjtliweTue, 19 May 2026 13:24:56 -0000Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

]]>Molecular Glues Roar, Plus Gene Therapy and Cell Therapy Newsfull5153falseWelcome to The Biotech Voyager. It's the show that covers what's next in biotech.Special Episode: ASGCT AftershowASGCT week moved fast. Too fast. So we’re doing a live aftershow on Monday, 11 AM to 12:30 PM EST to break down what happened at ASGCT 2026, the key insights, what surprised us, and what to watch next. Since this is a special one-off event, we will also stream this one live on Linkedin. We'll also have a special guest... so stay tuned. Come hang out with us. Add in your takeaways. See you there!flightcast:itv2z9y8qlr4lso3xti872ltTue, 19 May 2026 04:58:49 -0000ASGCT week moved fast. Too fast.
So we’re doing a live aftershow on Monday, 11 AM to 12:30 PM EST to break down what happened at ASGCT 2026, the key insights, what surprised us, and what to watch next.

Since this is a special one-off event, we will also stream this one live on Linkedin.

We'll also have a special guest... so stay tuned.

Come hang out with us.

Add in your takeaways.

See you there!

]]>Special Episode: ASGCT Aftershowfull4934falseASGCT week moved fast. Too fast. So we’re doing a live aftershow on Monday, 11 AM to 12:30 PM EST to break down what happened at ASGCT 2026, the key insights, what surprised us, and what to watch next. Since this is a special one-off event, we will also stream this one live on Linkedin. We'll also have a special guest... so stay tuned. Come hang out with us. Add in your takeaways. See you there!ASGCT 2026 Pre-Show: What to Watch in BostonThe Biotech Voyager is going live from 28 Capital's Back Bay offices on Monday to set the stage for ASGCT. We'll be covering the sessions, posters, and conversations worth your time this year, with guest appearances from NanoMosaic and Precede Bio sharing what they're bringing to the meeting. If you're heading to ASGCT or following from afar, tune in for a focused primer before the chaos begins.flightcast:xdqbr01qe4lblw7q0irkjr6kTue, 12 May 2026 06:25:26 -0000The Biotech Voyager is going live from 28 Capital's Back Bay offices on Monday to set the stage for ASGCT.
We'll be covering the sessions, posters, and conversations worth your time this year, with guest appearances from NanoMosaic and Precede Bio sharing what they're bringing to the meeting.
If you're heading to ASGCT or following from afar, tune in for a focused primer before the chaos begins.

]]>ASGCT 2026 Pre-Show: What to Watch in Bostonfull4315falseThe Biotech Voyager is going live from 28 Capital's Back Bay offices on Monday to set the stage for ASGCT. We'll be covering the sessions, posters, and conversations worth your time this year, with guest appearances from NanoMosaic and Precede Bio sharing what they're bringing to the meeting. If you're heading to ASGCT or following from afar, tune in for a focused primer before the chaos begins.Gene Therapy Using Ultrasound | Epigenetic Editors | $83M Series A for Gamma Delta T Cell EngagersHuge stories shaping the future of medicine this week. Researchers are using ultrasound to deliver gene therapy, bypassing traditional delivery methods entirely. Epigenetic editors are offering a new way to modify gene expression without cutting DNA. And a company developing gamma delta T cell engagers just closed an $83M Series A, a massive bet on a less explored branch of cancer immunotherapy. Ben and Jeff break down the science behind each story and what it means for the future of biotech. Tune in live Tuesdays and Thursdays at 11AM EST on The Biotech Voyager.flightcast:j3srn7jvwhv5ga4rilwm6p97Fri, 08 May 2026 05:16:13 -0000Huge stories shaping the future of medicine this week.

Researchers are using ultrasound to deliver gene therapy, bypassing traditional delivery methods entirely. Epigenetic editors are offering a new way to modify gene expression without cutting DNA. And a company developing gamma delta T cell engagers just closed an $83M Series A, a massive bet on a less explored branch of cancer immunotherapy.

Ben and Jeff break down the science behind each story and what it means for the future of biotech.

Tune in live Tuesdays and Thursdays at 11AM EST on The Biotech Voyager.

]]>Gene Therapy Using Ultrasound | Epigenetic Editors | $83M Series A for Gamma Delta T Cell Engagersfull6044falseHuge stories shaping the future of medicine this week. Researchers are using ultrasound to deliver gene therapy, bypassing traditional delivery methods entirely. Epigenetic editors are offering a new way to modify gene expression without cutting DNA. And a company developing gamma delta T cell engagers just closed an $83M Series A, a massive bet on a less explored branch of cancer immunotherapy. Ben and Jeff break down the science behind each story and what it means for the future of biotech. Tune in live Tuesdays and Thursdays at 11AM EST on The Biotech Voyager.The Cancer Vaccine Getting a Second Chance & The Future of Precision MedicineDiaconos Oncology just released new data in pancreatic cancer, one of the deadliest and hardest-to-treat cancers on the planet. But their approach isn't a typical drug. Ben and Jeff break down how dendritic cell vaccines work, why conventional cancer vaccines keep falling short, and what makes this approach different. Plus, RNA exon editing technology that rewrites disease at the RNA level without touching your DNA, and how AI is quietly transforming surgical pathology. New Episodes Monday, Tuesday and Thursday at 11am ESTflightcast:v0uq47qs5sgmum5xutbj0b5cTue, 05 May 2026 04:27:04 -0000Diaconos Oncology just released new data in pancreatic cancer, one of the deadliest and hardest-to-treat cancers on the planet. But their approach isn't a typical drug.

Ben and Jeff break down how dendritic cell vaccines work, why conventional cancer vaccines keep falling short, and what makes this approach different. Plus, RNA exon editing technology that rewrites disease at the RNA level without touching your DNA, and how AI is quietly transforming surgical pathology.

New Episodes Monday, Tuesday and Thursday at 11am EST

]]>The Cancer Vaccine Getting a Second Chance & The Future of Precision Medicinefull4130falseDiaconos Oncology just released new data in pancreatic cancer, one of the deadliest and hardest-to-treat cancers on the planet. But their approach isn't a typical drug. Ben and Jeff break down how dendritic cell vaccines work, why conventional cancer vaccines keep falling short, and what makes this approach different. Plus, RNA exon editing technology that rewrites disease at the RNA level without touching your DNA, and how AI is quietly transforming surgical pathology. New Episodes Monday, Tuesday and Thursday at 11am ESTIn vivo CAR-T's Impressive Streak, AI in Surgery & Cancer Vaccines, + John Boyce @ 28 CapitalIn vivo CAR-T keeps stacking wins, AI quietly invades the operating room, and cancer vaccines stage their second act... plus, John Boyce from 28 Capital joins the show. The show will break down the in vivo CAR-T streak that's reshaping how the industry thinks about cell therapy economics, dig into where AI is actually showing up in surgical workflows (and where the hype outpaces the data), and unpack why cancer vaccines are suddenly worth a second look after a decade in the wilderness. Then John Boyce from 28 Capital joins to talk early-stage biotech investing, what's catching his attention right now, and where he thinks the smart money is rotating in 2026.flightcast:rlfhan5tzywxdvelibu2xxbnThu, 30 Apr 2026 17:07:30 -0000In vivo CAR-T keeps stacking wins, AI quietly invades the operating room, and cancer vaccines stage their second act... plus, John Boyce from 28 Capital joins the show.

The show will break down the in vivo CAR-T streak that's reshaping how the industry thinks about cell therapy economics, dig into where AI is actually showing up in surgical workflows (and where the hype outpaces the data), and unpack why cancer vaccines are suddenly worth a second look after a decade in the wilderness.

Then John Boyce from 28 Capital joins to talk early-stage biotech investing, what's catching his attention right now, and where he thinks the smart money is rotating in 2026.

]]>In vivo CAR-T's Impressive Streak, AI in Surgery & Cancer Vaccines, + John Boyce @ 28 Capitalfull7337falseIn vivo CAR-T keeps stacking wins, AI quietly invades the operating room, and cancer vaccines stage their second act... plus, John Boyce from 28 Capital joins the show. The show will break down the in vivo CAR-T streak that's reshaping how the industry thinks about cell therapy economics, dig into where AI is actually showing up in surgical workflows (and where the hype outpaces the data), and unpack why cancer vaccines are suddenly worth a second look after a decade in the wilderness. Then John Boyce from 28 Capital joins to talk early-stage biotech investing, what's catching his attention right now, and where he thinks the smart money is rotating in 2026.The Craziest Immunotherapy We've Ever Seen + CNS Gene Therapy BoomAsgard's AT-108 might be the most insane immunotherapy of 2026. .. a first-in-class in vivo cell reprogramming play for cancer. Meanwhile, CNS gene therapy is having a moment: AviadoBio is crossing the blood-brain barrier, Avista's AI-designed capsids are heading to the eye and CSF, and Tenaya just dropped one-year cardiac gene therapy data at ASGCT. Plus: Dr. Nicole Paulk joins live! Her work on CNS-directed AAV gene therapy for glioma puts her right at the center of where this field is heading. Live on the Biotech Voyager. (Both YouTube and Linkedin)flightcast:ess7adbrljqu6veeykt6be0gWed, 29 Apr 2026 05:25:34 -0000Asgard's AT-108 might be the most insane immunotherapy of 2026. .. a first-in-class in vivo cell reprogramming play for cancer.
Meanwhile, CNS gene therapy is having a moment: AviadoBio is crossing the blood-brain barrier, Avista's AI-designed capsids are heading to the eye and CSF, and Tenaya just dropped one-year cardiac gene therapy data at ASGCT.
Plus: Dr. Nicole Paulk joins live! Her work on CNS-directed AAV gene therapy for glioma puts her right at the center of where this field is heading.

Live on the Biotech Voyager.
(Both YouTube and Linkedin)

]]>The Craziest Immunotherapy We've Ever Seen + CNS Gene Therapy Boomfull5380falseAsgard's AT-108 might be the most insane immunotherapy of 2026. .. a first-in-class in vivo cell reprogramming play for cancer. Meanwhile, CNS gene therapy is having a moment: AviadoBio is crossing the blood-brain barrier, Avista's AI-designed capsids are heading to the eye and CSF, and Tenaya just dropped one-year cardiac gene therapy data at ASGCT. Plus: Dr. Nicole Paulk joins live! Her work on CNS-directed AAV gene therapy for glioma puts her right at the center of where this field is heading. Live on the Biotech Voyager. (Both YouTube and Linkedin)